Trial Profile

Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary)
Indications Renal transplant rejection
Focus Pharmacogenomic; Therapeutic Use
Acronyms RITUX-ERAH

Most Recent Events

06 Jun 2018 Results presented at the 2018 American Transplant Congress
09 Nov 2015 Results published in the Transplantation
10 Sep 2013 Results presented at the 16th Congress of the European Society for Organ Transplantation.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com